Literature DB >> 10366566

Tetracycline-mediated regulation of gene expression within the human cytomegalovirus genome.

M A McVoy1, E S Mocarski.   

Abstract

To evaluate the utility of tetracycline gene regulation in the study of human cytomegalovirus gene functions, expression of luciferase under the control of tetracycline-regulatable promoters was studied following transient plasmid transfections and from within recombinant human cytomegalovirus genomes. The tetracycline-regulatable promoter PhCMV*-1 contains sequences from the human cytomegalovirus ie1/ie2 promoter and seven upstream tet operator sites which bind the activator protein tTA only in the absence of tetracycline (Gossen and Bujard (1992). Proc. Natl. Acad. Sci. USA 89, 5547-5551). Two modifications of PhCMV*-1 were also studied: P1129, in which the tet operator sites were reduced from seven to one; and P1125, in which human cytomegalovirus sequences were replaced by adenovirus major late promoter and terminal deoxynucleotidyltransferase initiator sequences. In transient assays, PhCMV*-1 and P1125 exhibited modest differential regulation but were strongly activated by viral infection. P1129 exhibited less viral activation and narrower regulation. In the viral genome, PhCMV*-1 exhibited regulation up to 7-fold during late times of infection, whereas P1125 displayed nearly 100-fold regulation. Regulation of P1125 was fully reversed within 12 to 24 h of adding or removing tetracycline. These results suggest that P1125 may provide sufficient conditional expression to effectively regulate human cytomegalovirus late genes. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366566     DOI: 10.1006/viro.1999.9724

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Conditional cytomegalovirus replication in vitro and in vivo.

Authors:  Brigitte Rupp; Zsolt Ruzsics; Torsten Sacher; Ulrich H Koszinowski
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants.

Authors:  E M Borst; G Hahn; U H Koszinowski; M Messerle
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Perivascular stromal cells as a potential reservoir of human cytomegalovirus.

Authors:  M A Soland; L R Keyes; R Bayne; J Moon; C D Porada; S St Jeor; G Almeida-Porada
Journal:  Am J Transplant       Date:  2014-03-04       Impact factor: 8.086

4.  Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.

Authors:  Sukhada Bhave; Howard Elford; Michael A McVoy
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

5.  Antiviral activities of four marine sulfated glycans against adenovirus and human cytomegalovirus.

Authors:  Mary Zoepfl; Rohini Dwivedi; Maggie C Taylor; Vitor H Pomin; Michael A McVoy
Journal:  Antiviral Res       Date:  2021-04-14       Impact factor: 10.103

6.  Analysis of essential viral gene functions after highly efficient adenofection of cells with cloned human cytomegalovirus genomes.

Authors:  Endrit Elbasani; Ildar Gabaev; Lars Steinbrück; Martin Messerle; Eva Maria Borst
Journal:  Viruses       Date:  2014-01-23       Impact factor: 5.048

7.  Anti-cytomegalovirus activity of the anthraquinone atanyl blue PRL.

Authors:  Zohaib Alam; Zainab Al-Mahdi; Yali Zhu; Zachary McKee; Deborah S Parris; Hardik I Parikh; Glen E Kellogg; Alison Kuchta; Michael A McVoy
Journal:  Antiviral Res       Date:  2014-12-10       Impact factor: 5.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.